Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chevron

Coca-Cola

Altria

Procter & Gamble

Verizon

In a volatile stock market, navigating investment avenues that promise reliable returns remains a key priority for investors. The article delves into the world of income-centric investments.

Income Kings: 7 Blue-Chip Dividend Stocks for Reliable Returns

Johnson & Johnson JNJ, +0.32% said Thursday that its medical technology segment has acquired medical device maker Laminar Inc. in a deal that will reduce its full-year 2023 and 2024 earnings per share. The company said it paid $400 million up front for the privately held Laminar, which makes devices for patients with non-valvular atrial fibrillation, a condition that raises patients' risk of having a stroke.

Johnson & Johnson buys medical device maker Laminar, cuts full-year earnings guidance

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond.

Johnson & Johnson MedTech Acquires Laminar, Inc.

Under current market conditions, our view is that playing defensive is more important than pursuing growth. Against this overall backdrop, this article explains why Johnson & Johnson is a good defensive stock. Johnson & Johnson satisfies all the requirements that Benjamin Graham promoted for picking defensive stocks.

Johnson & Johnson, Ben Graham, And Defensive Stocks

AbbVie

Eli Lilly

Pfizer

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

4 Large Drug Stocks to Watch as IBD Market Gains Traction

Gilead Sciences

Bemis Company

Johnson & Johnson NYSE: JNJ,  Gilead Sciences Inc. NYSE: GILD and Bristol Myers Squibb Co. NYSE: BMY are among healthcare sector dividend-payers trading at low valuations relative to their earnings.

J&J, Gilead, BMS: A look at undervalued dividend payers

ARM Holdings PLC

Birkenstock Holding Plc

Cava Group, Inc.

Golden Heaven Group Holdings Ltd

Kenvue

NEXTracker Inc

Rivian Automotive

So far in 2023, 146 companies have gone public in the U.S. markets, down 16.09% from the same time last year. Although the IPO market has been choppy amid higher interest rates and broad equity market uncertainty, the new companies as a whole have outperformed the S&P 500.

2023's most anticipated IPOs weren't always the big winners

Apple

Microsoft

Here's a look at the anatomy of blue-chips stocks along with five top picks for the upcoming year.

5 Best Blue-Chip Stocks For 2024

Brown & Brown

Chubb

Church & Dwight

Hormel Foods

Jack Henry & Associates

Medtronic

Public Service Enterprise Group

SPDR S&P 500 ETF Trust

In my monthly series of 10 Dividend Growth Stocks, I rank a selection of Dividend Radar stocks and present the 10 top-ranked stocks for further research and possible investment. This month, I'm presenting high-quality stocks with the highest defensiveness scores based on a scoring system developed by David Van Knapp. I ranked candidates by considering, in turn, their Dividend Safety Scores and their Beta measure of volatility.

10 Dividend Growth Stocks For November 2023

Waste Connections

U.S. stock market indexes are coming off of four positive weeks, but some top dividend stocks haven't kept pace. Johnson & Johnson stock is trading near a 52-week low despite strong growth from its medical technology and pharmaceutical businesses.

2 Unstoppable Dividend Stocks Trading Near 52-Week Lows to Buy Now

Sirius XM Holdings Inc

There are few investors who have their every move followed and analyzed like Berkshire Hathaway (NYSE: BRK-A )(NYSE: BRK-B ) chairman and CEO Warren Buffett. That's because none have the sustained, long-term success of the Oracle of Omaha.

The Shocking Stock That Warren Buffet Just Bought (and 2 He Sold)

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech stocks to check out in the stock market today.

3 Biotech Stocks To Watch Before December 2023

The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1 Protagonist eligible to receive $115 million milestone upon achieving the co-primary endpoints in any one of the studies NEWARK, CA / ACCESSWIRE / November 27, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced two additional Phase 3 studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ-2113 (formerly PN-235) in head-to-head comparisons against deucravacitinib, an oral TYK2 inhibitor, in patients with moderate-to-severe psoriasis. Details regarding ADVANCE 1 are available on clinicaltrials.gov.

Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib

Amazon

Broadcom

Alphabet

NVIDIA

Tesla

UnitedHealth Group

Exxon Mobil

For years now, a significant cohort of investors gravitated towards the allure of the S&P 500 index over individual stocks.

Investing $10K in S&P 500 buys this much of largest stocks

Archer-Daniels-Midland Company

Black Hills

Emerson Electric

Federal Realty Investment Trust

Gorman-Rupp

Leggett & Platt

National Fuel Gas

Northwest Natural Gas

Universal Corp

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years." - Dogs of the Dow. The 49 Dividend Kings screened as of November 22 represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gains ranged 18.52%-38.49% topped by Northwest Natural and Gorman-Rupp. By yield, Altria tops all. Top-ten Kingly December yields reported for NFG, ABBV, FRT, BKH, NWN, UVV, CDUAF, MMM, LEG, & MO averaged 5.86%.

Buy 6 December Dividend Kings, 4 More On Watch

News for Johnson & Johnson Stock (JNJ)